Table 5.
Summary of new and emerging treatments in psoriasis and psoriatic arthritis (PsA)
| MOA | Drug | Manufacturer | Trial phase completeda | Ongoing trialsa | Preliminary efficacy data |
|---|---|---|---|---|---|
| PDE4 inhibitor | Apremilast | Celgene | Phase II, III |
Phase III ESTEEM (psoriasis), PALACE (PsA) |
Psoriasis [177] |
| JAK | Tofacitinib | Pfizer | Phase II | Phase III psoriasis + PsA (NCT01519089) | Psoriasis [186, 187] |
| Anti-IL-17 agents | Secukinumab (AIN-457) | Novartis | Phase II |
Phase III Psoriasis (NCT01365455) PsA (NCT01392326) |
Psoriasis [196–198] |
| Brodalumab (AMG 827) | Amgen | Phase II |
Phase III Psoriasis (NCT01708603 and NCT01708629) |
Psoriasis [191] PsA [192] |
|
| Ixekizumab (LY2439821) | Eli Lilly | Phase II |
Phase III Psoriasis (NCT01474512) PsA (NCT01695239) |
Psoriasis [193] | |
| Protein kinase C inhibitor | Sotrastaurin (AEB071) | Novartis | Phase II | None | Psoriasis [194] |
| Adenosine A3 receptor inhibitor | CF101 | Can-Fite BioPharma | Phase II |
Phase II/III Psoriasis (NCT01265667) |
Psoriasis [195] |
| Calcineurin inhibitor | Voclosporin (ISA247) | Isotecknika | Phase III | None | Psoriasis [200] |
| Additional compounds in development for psoriasis or RA | |||||
| JAK1, JAK2 inhibitor | LY3009104 (INCB28050, INCYTE) | Eli Lilly | Phase IIb study ongoing in psoriasis (NCT01490632) | ||
| JAK3 inhibitor | VX-509 | Vertex Pharmaceuticals | |||
| JAK inhibitor | ASP015K | Astellas Pharma | Phase IIa trial in psoriasis completed (NCT01096862) | In phase IIb development for RA | |
| IL-12/IL-23 synthesis inhibitor | Aplimod (STA-5326) | Synta Pharmaceuticals | |||
| IL-23 blocker | SCH 900222 | Merck | Phase II trial in psoriasis completed (NCT01225731) | Phase III trial in psoriasis planned (NCT01722331) | |
| Regulatory T cell activator | BT-061 | Biotest | Phase II trial in psoriasis completed (NCT01072383) | Phase II trial in RA ongoing (NCT01481493) | |
| S1P1 receptor blocker | ACT-128800 | Actelion | |||
| p38 MAPK blocker | BMS-582949 | Bristol-Myers Squibb | Phase I/II trial in psoriasis completed; patent filed in 2012 for treatment of RA (see http://www.highbeam.com/doc/1P3-2609565631.html) | ||
| Fumaric acid | FP187 | Forward-Pharma | Currently in phase II development for psoriasis (see http://www.forward-pharma.com/about_us.html) | ||
| Anti-inflammatory (MOA proprietary) | LEO22811 | LEO Pharma | Currently in phase II development for ‘inflammatory indications’ (see http://www.leo-pharma.us/Home/Research-and-Development/LEO-Pharma-Global-Pipeline.aspx) | ||
| Sirtuin activator | SRT2104 | GlaxoSmithKline | Phase II study in psoriasis complete (NCT01154101) | ||
| Oxidized phospholipid | VB-201 | VBL Therapeutics | Phase II study in psoriasis complete (NCT01001468) | ||
ESTEEM Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis, IL interleukin, JAK Janus kinase, MAPK mitogen-activated protein kinase, MOA mechanism of action, PALACE Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy, PDE phosphodiesterase, RA rheumatoid arthritis, S1P1 sphingosine-1-phosphate receptor 1
aThe NCT numbers are ClinicalTrials.gov study identifiers